Evidence map›Paper›PMID 37675979›Full record

ArticlemAbs

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT.

Sj J Diong, Aarti Jashnani, Andrew W Drake, Christine Bee, Felix Findeisen, Gavin Dollinger, Feng Wang, Arvind Rajpal, Pavel Strop, Peter S Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Sj J DiongDiscovery Biologics, Bristol Myers Squibb, Redwood City, CA, USA.ORCID 0000-0002-4516-8355
Aarti JashnaniDiscovery Biologics, Bristol Myers Squibb, Redwood City, CA, USA.
Andrew W DrakeDiscovery Biologics, Bristol Myers Squibb, Redwood City, CA, USA.
Christine BeeBiochemistry and Biophysics, Merck, South San Francisco, CA, USA.
Felix FindeisenDiscovery Biologics, Bristol Myers Squibb, Redwood City, CA, USA.
Gavin DollingerDiscovery Biologics, Bristol Myers Squibb, Redwood City, CA, USA.
Feng WangLarge Molecule Drug Discovery, Genentech Research and Early Development, South San Francisco, CA, USA.
Arvind RajpalLarge Molecule Drug Discovery, Genentech Research and Early Development, South San Francisco, CA, USA.
Pavel StropResearch, Tallac Therapeutics, Burlingame, CA, USA.
Peter S LeeAntibody Engineering, AbbVie, South San Francisco, CA, USA.
Bristol-Myers Squibb (Germany) · DEAbbVie (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USTalaris Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical successes of immune checkpoint blockade have invigorated efforts to activate T cell-mediated responses against cancer. Targeting members of the PVR family, consisting of inhibitory receptors TIGIT, CD96, and CD112R, has been an active area of clinical investigation. In this study, the binding interactions and molecular assemblies of the PVR family receptors and ligands have been assessed

Indexed as

NeoplasmsReceptors, ImmunologicAntibodies, MonoclonalHumansLigandsT-LymphocytesAntibodies, MonoclonalLigandsReceptors, ImmunologicTIGIT protein, humanAntibodybiophysicsimmunologyoncologyreceptor–ligand interactions

Identifiers

PMID37675979
PMCPMC10486284
OpenAlexW4386496933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.